| | |

AHRP Position Statement on Mental Health Screening – FDA Hearing Re: Drug Advertising

AHRP Position Statement on Mental Health Screening – FDA Hearing Re: Drug Advertising Wed, 02 Nov 2005 FDA is holding public hearings (Nov 1, 2) Re:  Direct-to-Consumer Promotion of Medical Products at: National Transportation Safety Board Boardroom and Conference Center 429 L’Enfant Plaza, SW., Washington, DC 2 Time: 9:00 –5:00….

Recycled drugs: failed antidepressants– Stratera marketed for ADHD; Cymbalta for incontinence

Recycled drugs: failed antidepressants– Stratera marketed for ADHD; Cymbalta for incontinence Mon, 26 Apr 2004 A front page article in The Wall Street Journal (excerpt below) provides a roadmap of failed Eli Lilly drugs which the company repackaged for a different condition than the one for which the drugs had…

Hoffman LaRoche Rebuffed Call to Monitor Accutane Users – USA Today

Hoffman LaRoche Rebuffed Call to Monitor Accutane Users – USA Today Tue, 7 Dec 2004 An investigative cover story in USA Today – Drugmaker Rebuffed Call to Monitor Users–affirms the indispensable role of litigation in bringing the facts about adverse drug effects to public knowledge. Lawsuits against Hoffman-La Roche, manufacturer…

Antipsychotic Drug Use Doubled since 1996 in Tennessee Children – Why?

Antipsychotic Drug Use Doubled since 1996 in Tennessee Children – Why? Thu, 2 Sep 2004 A Vanderbilt University study found that the use of antipsychotic drugs has doubled among poor children in Tennessee. “The increase, seen largely among children diagnosed with attention-deficit/hyperactivity disorder (ADHD), conduct disorder and affective disorders such…

Pharma Efforts to Bar Placebo Responders from Trials – WSJ

Pharma Efforts to Bar Placebo Responders from Trials – WSJ Fri, 25 Jun 2004 A clinical trial report in The Lancet debunks the value of Aricept, a popular drug prescribed for Alzheimer’s patients. The findings of a three-year placebo controlled trial show that: “Although the patients taking the drug did…

Psychiatric Drugs Pushing Children to Crisis Units_Tampa Tribune

Psychiatric Drugs Pushing Children to Crisis Units_Tampa Tribune Tue, 15 Apr 2003 A report in the Tampa Tribune following its five month investigation, shows how misprescribing of psychiatric drugs for children can precipitate life-threatening tragedies. The report describes a 9 year old child’s descent into suicidal violence after she had…

Anti-malaria drug: Risk of Suicide

Anti-malaria drug: Risk of Suicide_UPI Thu, 29 Aug 2002 United Press International (UPI) reporters, Mark Benjamin and Dan Olmsted, have conducted a 6 month investigation of the reports linking the antimalaria drug, Lariam to severe mental disorders–including violence and suicide. http://www.upi.com/results.cfm?Keywords=lariam On May 21, UPI reported that “in thousands of…

AHRP in the News

Alliance for Human Research Protection in the Press Feb 17, 2005: FDA Critics Slam Plan for Safety Reform – Nature “This is smoke and mirrors and musical chairs,” says Vera Sharav, president of the New York-based Alliance for Human Research Protection. “They will be using the very same officials that…

Science Refutes Claims of Drug Benefit: Antipsychotics Found Harmful_NEJM

"The drugs most commonly used to soothe agitation and aggression in people with Alzheimer’s disease are no more effective than placebos for most patients, and put them at risk of serious side effects, including confusion, sleepiness and Parkinson’s disease-like symptoms, researchers are reporting
today."

FDA Suspends ADHD Drug Safety Study-Approves Risperdal for Autistic Children Without Public Hearing

Two actions by the FDA last week demonstrate where the agency’s priority lies—and that priority is NOT to protect public safety, NOT to protect children’s safety. FDA’s priority—as demonstrated by its actions—is approval of new drugs or approval for expanded even dubious uses of patented drugs.